Apollomics Inc Cl A (APLM)

$18.43 +6.25 (51.34%)
Market Cap 20.34M
Revenue (ttm) 1.49M
Net Income (ttm) -53.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,614.77%
Debt to Equity Ratio 0.00
Volume 682,200
Avg Vol 64,924
Day's Range N/A - N/A
Shares Out 1.10M
Stochastic %K 84%
Beta 0.90
Analysts Strong Buy
Price Target $6.50

Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multip...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 209 4055
Fax: 650 288 1674
Address:
989 East Hillsdale Blvd., Suite 220, Foster City, United States
Dr24stock
Dr24stock Oct. 4 at 5:48 PM
$APLM maybe find a real one?!
0 · Reply
svenqqq
svenqqq Oct. 3 at 5:22 PM
$APLM my broker says this opens in days and not months
1 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 7:27 AM
$APLM Great piece that accurately captures APLM's current position. So if you want to refresh your understanding of APLM or learn about APLM for the first time, this is essential reading. https://beyondspx.com/quote/APLM/analysis/apollomics-unlocking-oncology-s-future-through-targeted-innovation-nasdaq-aplm
0 · Reply
GhostAtlas
GhostAtlas Oct. 3 at 2:33 AM
$JL $MYNZ $APLM $PBM _
0 · Reply
HouseOfTheDragons
HouseOfTheDragons Oct. 3 at 2:31 AM
Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Also watching for breakout: $AMBI $AMST $APLM $APM !
0 · Reply
Danomighty
Danomighty Oct. 1 at 4:29 PM
$APLM how much money is tied up in this stock lol
3 · Reply
IsabellaDC
IsabellaDC Oct. 1 at 1:32 PM
Movers at open. $APLM $PALI $GLXG $LAC $NVA and so. Let the market breathe...
0 · Reply
SadyK189
SadyK189 Oct. 1 at 2:15 AM
Top Stocks to watch tomorrow 2 / 2: $AQB $APLM $DNUT $SPRU $YQ AQB: Initially alerted at 1.11. Still looking good on daily chart. key support at 1.65 - 1.80. Next key level to test is 2.6 - 2.85. Currently at 2.20 APLM: Looking good on daily chart. Key support at 14.30 - 15.10. Next key level to test is 21 - 24. It may take sometime though. Currently at 18 YQ is trending nicely on daily chart. 3.3 - 3.6 is acting as key support zone. Next key level to test is 4.85 - 5.10. Currently at 4.38 SPRU: Looking good on 4hours chart. Key support at 1.9 - 2.10. Next key level to test is 2.95 - 3.15. Currently at 2.53 DNUT: Good close of daily candle. 3 - 3.25 is acting as key support zone. Next key level to test is 4.35 - 4.55. Currently at 3.87
2 · Reply
IsabellaDC
IsabellaDC Sep. 30 at 2:57 PM
High Movers of the day: $ZYBT $APLM $EPOW $SPRC $WOLF and so on... Stay green people.
2 · Reply
Dr24stock
Dr24stock Sep. 30 at 9:42 AM
$APLM 1 week after panel hearing (in 2 to 3 months). Otc tho.
1 · Reply
Latest News on APLM
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apr 3, 2025, 4:05 PM EDT - 6 months ago

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Mar 31, 2025, 8:00 AM EDT - 6 months ago

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 20, 2024, 8:00 AM EST - 10 months ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 10, 2024, 4:05 PM EST - 10 months ago

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 14, 2024, 6:00 AM EDT - 1 year ago

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Jul 16, 2024, 4:47 PM EDT - 1 year ago

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 3:57 PM EDT - 1 year ago

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Mar 4, 2024, 7:00 AM EST - 1 year ago

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 7:00 AM EST - 1 year ago

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 19, 2024, 4:15 PM EST - 1 year ago

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Jan 17, 2024, 4:30 PM EST - 1 year ago

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jan 3, 2024, 7:00 AM EST - 1 year ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics to Present at the 2024 Biotech Showcase

Jan 2, 2024, 4:30 PM EST - 1 year ago

Apollomics to Present at the 2024 Biotech Showcase

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 29, 2023, 7:30 AM EST - 2 years ago

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Nov 28, 2023, 7:00 AM EST - 2 years ago

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Nov 16, 2023, 8:30 AM EST - 2 years ago

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Oct 26, 2023, 8:50 AM EDT - 2 years ago

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Oct 23, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Oct 16, 2023, 6:55 PM EDT - 2 years ago

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Sep 28, 2023, 4:17 PM EDT - 2 years ago

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Aug 29, 2023, 6:21 AM EDT - 2 years ago

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

Apr 26, 2023, 7:45 AM EDT - 2 years ago

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

ANGO

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Jan 13, 2023, 4:13 PM EST - 2 years ago

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Oct 7, 2022, 4:05 PM EDT - 3 years ago

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Dr24stock
Dr24stock Oct. 4 at 5:48 PM
$APLM maybe find a real one?!
0 · Reply
svenqqq
svenqqq Oct. 3 at 5:22 PM
$APLM my broker says this opens in days and not months
1 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 7:27 AM
$APLM Great piece that accurately captures APLM's current position. So if you want to refresh your understanding of APLM or learn about APLM for the first time, this is essential reading. https://beyondspx.com/quote/APLM/analysis/apollomics-unlocking-oncology-s-future-through-targeted-innovation-nasdaq-aplm
0 · Reply
GhostAtlas
GhostAtlas Oct. 3 at 2:33 AM
$JL $MYNZ $APLM $PBM _
0 · Reply
HouseOfTheDragons
HouseOfTheDragons Oct. 3 at 2:31 AM
Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Also watching for breakout: $AMBI $AMST $APLM $APM !
0 · Reply
Danomighty
Danomighty Oct. 1 at 4:29 PM
$APLM how much money is tied up in this stock lol
3 · Reply
IsabellaDC
IsabellaDC Oct. 1 at 1:32 PM
Movers at open. $APLM $PALI $GLXG $LAC $NVA and so. Let the market breathe...
0 · Reply
SadyK189
SadyK189 Oct. 1 at 2:15 AM
Top Stocks to watch tomorrow 2 / 2: $AQB $APLM $DNUT $SPRU $YQ AQB: Initially alerted at 1.11. Still looking good on daily chart. key support at 1.65 - 1.80. Next key level to test is 2.6 - 2.85. Currently at 2.20 APLM: Looking good on daily chart. Key support at 14.30 - 15.10. Next key level to test is 21 - 24. It may take sometime though. Currently at 18 YQ is trending nicely on daily chart. 3.3 - 3.6 is acting as key support zone. Next key level to test is 4.85 - 5.10. Currently at 4.38 SPRU: Looking good on 4hours chart. Key support at 1.9 - 2.10. Next key level to test is 2.95 - 3.15. Currently at 2.53 DNUT: Good close of daily candle. 3 - 3.25 is acting as key support zone. Next key level to test is 4.35 - 4.55. Currently at 3.87
2 · Reply
IsabellaDC
IsabellaDC Sep. 30 at 2:57 PM
High Movers of the day: $ZYBT $APLM $EPOW $SPRC $WOLF and so on... Stay green people.
2 · Reply
Dr24stock
Dr24stock Sep. 30 at 9:42 AM
$APLM 1 week after panel hearing (in 2 to 3 months). Otc tho.
1 · Reply
CBVols
CBVols Sep. 29 at 12:27 PM
$APLM when will this open again?
0 · Reply
Pinhus
Pinhus Sep. 26 at 5:19 PM
$APLM This company is pure fraud. They don’t answer any emails AND they don’t answer any phone calls. Prove me wrong! PS. They would be SUPER LUCKY if they’re back on the exchange…
1 · Reply
Dr24stock
Dr24stock Sep. 26 at 2:02 PM
$APLM i ve never seen an appeal saying "yeah, u re right". Esp from the to be delisted companies...
0 · Reply
bmts
bmts Sep. 26 at 1:00 PM
$APLM what will happens longs and shorts if it is not open at all.
2 · Reply
Vasi999
Vasi999 Sep. 26 at 9:57 AM
$APLM It will open at 40$!
1 · Reply
Dr24stock
Dr24stock Sep. 25 at 10:10 PM
$APLM panel hearing is different from t12 halt. Any hope here is pointless, except for 99% drop to otc. And even that isnt guaranteed.
2 · Reply
ilaz55
ilaz55 Sep. 25 at 8:42 PM
$APLM positive news
1 · Reply
Pitts123
Pitts123 Sep. 25 at 5:34 PM
$APLM They might have been better off just going OTC briefly with the momentum they just had and reapplied to up list later.
0 · Reply
stanmanrich
stanmanrich Sep. 25 at 3:05 PM
$APLM Lovely. Hoping for a successful appeal.
0 · Reply
Dr24stock
Dr24stock Sep. 25 at 3:02 PM
$APLM "completed the filing of the application to apeal"... wow. Hope that means they ve appealed. Geezusss. Also hope they ve answered the request for Information and get unhalted before panel hearing.
0 · Reply
uks
uks Sep. 25 at 2:20 PM
$APLM they filed it on 23rd sep https://www.einnews.com/pr_news/852261836/apollomics-announces-completion-of-filing-of-appeal-of-nasdaq-delisting-order
0 · Reply
Dr24stock
Dr24stock Sep. 25 at 12:58 PM
$APLM today is the last day the would file for that and let us know in a coupl2 of days. Nothing is happening.
0 · Reply